semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Lymphocytic Leukemia Clinical diagnosis with CLL Clinical decision made to initiate first-line therapy, second-line therapy or subsequent line of therapy prior to enrollment into the ConnectTM CLL registry, but within 2 months of enrollment Age≥18 years Willing and able to provide signed informed consent Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel  Participation in a clinical study in which study treatment is blinded Patient condition is considered terminal (i.e.<6 months to live)
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Type 2 Diabetes Hypogonadism male patients with type 2 diabetes mellitus T2DM as judged by WHO onset of diabetes mellitus after the age of 30 years blood glucose controlled by diet or drugs other than insulin, or insulin initiated after 2 years diagnosis of diabetes no history of diabetic ketoacidosis Symptomatic Hypogonadism as defined by Total testosterone below 10 nmol/l Aging males' symptom score (AMS) above 36 Hypogonadic men with erectile dysfunction Age range  Patients with uncontrolled hypertension (BP>145/95 on treatment) or significant hypotension. (BP<100 systolic) Current smokers Recent myocardial infarction (<6 months), unstable angina or ongoing chest pain, recent (within 6 months) cardiac intervention (e.g. angioplasty, stenting or CABG) or stroke Patients with clinical nephropathy (24 hr protein >0.5 g or urine protein +) or moderate renal failure (serum creatinine >150 micromol/l) History of prostate cancer or suspicion of prostate cancer on clinical examination Androgen dependent carcinoma of the male mammary gland Liver tumours Hypersensitivity to or Polycythaemia General systemic illness, including cardiac, renal or hepatic insufficiency
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Patients who have given their informed consent and expressed interest in participating in the study Asthmatic Patients  Patients with communication difficulties Persons who obtain symbicort but not for their own use Patients with other major diseases: Heart problems, COPD, lung cancer, AIDS Patients with a respiratory infection Patients with seasonal asthma Pregnant women Patients who have previously participated in a health education study in asthma
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Understand and voluntarily sign the informed consent and HIPAA forms Age >18 years at the time of signing the informed consent Scheduled for epiduroscopy assisted epidural neurolysis A diagnosis of low back pain with or without radiculopathy  Not scheduled for epiduroscopy assisted epidural neurolysis In the opinion of the investigator, the patient's overall condition is not suitable for
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pain Patient ≥ 18 years-old, male or female, whatever his/her ethnic group Patient with untreatable cancer Patient hospitalized in a palliative care unit, with a life expectancy ≥ 1 week Pain unresponsive to conventional treatments Effectiveness of the injection test Signed informed consent  Patients > 18 years-old Patients with pain other than cancer pain Patient's refusal Coagulation disorders Local infection Known hypersensitivity to local analgesics Inefficacy of the injection test Contraindication for analgesics
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Abdominal Pain Elderly (65 years or older) patients with non-traumatic UAP of less than 48 hours' duration were included in the study. Participants were required to have a UAP and report either "mild" or greater pain intensity on a four-point verbal rating scale (VRS) or at least 20 mm on a 100 mm visual analogue scale (VAS)  included known allergy or contraindication to morphine, or any opioid analgesic Hemodynamic instability (systolic blood pressure less than 100 mm-Hg) Use of any analgesic within 6 hours before ED presentation Patients refused to participate to the study Incooperated to the VAS Isolated flank pain or previous study enrollment Patients with known renal, pulmonary, cardiac or hepatic failure were also excluded
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  ST Elevation (STEMI) Myocardial Infarction of Other Sites *Selection Any patient hospitalised in the CCU of the participating centers with a diagnosis of a first MI with ST segment elevation and/or Q wave at admission with troponin elevation seen within the first 24 hours after symptom onset aged between 18 and 80 years is selected consent emergency clause: His/her informed consent is obtained and he/she signs the consent form or However, if a member of the patients' family is present, his/her consent must be obtained or no consent *Inclusion The first transthoracic echocardiography is performed at day 4±2 in all patients selected In the presence of at least 3 akinetic LV segments at the transthoracic echocardiography, the patient is included  *Non-selection Informed consent not obtained Patients with diagnosis of previous MI, hypertrophic or dilated cardiomyopathy, significant valvular heart disease, chronic atrial fibrillation, or pace maker or any permanently implanted device susceptible to interfere with LV remodelling Patients with preexisting heart failure Patients having undergone previous cardiac surgery Patients having received chemotherapy susceptible to induce LV remodeling (anthracyclines) Patients with an associated short-time life-threatening disease Patients with poor echogenicity Patients without health insurance
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pancreatitis 18 years or older 2. Able to provide consent 3. More than one documented episode of pancreatitis (>3 fold elevation of amylase and or lipase with abdominal pain or with body imaging consistent with pancreatitis: need two of the three) 4. Subjects with abdominal pain and enzyme elevation which is <3 fold above normal or absence of imaging findings: these subjects who are undergoing endoscopic interventions but do not fit the "classic criteria" for pancreatitis will be included but the analysis of data of these subjects would be done separately. Note: subjects with a diagnosis of pancreas divisum and or Sphincter of Oddi dysfunction diagnosed prior to or after entry into the study will be included in the study but their data will be analyzed separately because of the controversy regarding the association of these entities with pancreatitis  Unable to give informed consent. 2. Definite evidence of biliary or alcoholic pancreatitis. 3. Clear evidence of hypertriglyceridemia-induced pancreatitis (triglycerides >1,000 mg/dl). 4. Post-ERCP pancreatitis, drug-induced pancreatitis, or any identifiable cause for pancreatitis. 5. History of pancreatic surgery
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.083-0.583,  Hydronephrosis Urinary Tract Infection Infants with AHN (one to seven months of age) confirmed postnatally with renal-bladder ultrasound and/or a dilated ureter ≥ 7mm 2. SFU grade III and IV AHN (high grade hydronephrosis) 3. Patients without grades II to V VUR determined by voiding cystogram (includes UPJO-like and primary megaureter (hydroureteronephrosis) only); 4. Parent or legal guardian able to give free and informed consent  Infants with grades II to V VUR 2. Infants with posterior urethral valves or Prune-Belly syndrome 3. Duplication anomalies (ureteroceles, ectopic ureters) 4. Other conditions that may require chronic use of antibiotics 5. Previous renal failure 6. Allergy to trimethoprim 7. Co-enrollment in another intervention trial
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 55.0-75.0,  Type 2 Diabetes Mellitus Men and women with type 2 diabetes From 55-75 years of age (Women post-menopausal for at least 5 years) Sedentary: < 3 bouts of planed physical activity of >30 min per week  Smoking (defined as more than one cigarette per day) Inability to speak and read English Diseases known to affect body fat distribution (e.g., polycystic ovary syndrome, Cushing's syndrome, HIV-AIDS or lipodystrophies) Taking medications that may affect body fat distribution (e.g., Thiazolidinedione, Insulin, Growth Hormone) Limitations to regular exercise training (e.g., musculoskeletal limitations, heart disease, chronic obstructive pulmonary disease) Answering "yes" to any of the questions on the physical activity readiness questionnaire (PAR-Q) Having undergone major changes in physical activity, diet or medication in the previous 6 months (or be planning such changes in the next 4 months). Changes in physical activity will be considered as an increase or decrease of more than 1 hour per week. A change in body weight greater 3 kg will also lead to exclusion Body weight > 300 lbs (maximum weight for Dual Energy X-Ray Absorptiometry (DXA) table) HbA1c > 0.09% blood pressure above 140/90 mmHg
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Is the individual a healthy, normal adult man or non-child bearing potential woman who volunteers to participate? Is s/he at least 18 years of age? Is his/her BMI between 19 and 30, inclusive? Is s/he considered reliable and capable of understanding his/her responsibility and role in the study? Has s/he provided written informed consent?  Does the individual have a history of allergy or hypersensitivity to zonisamide or sulfonamides? Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have serious psychological illness? Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse? Does s/he have a positive urine drug screen, or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test? Has s/he consumed grapefruit or grapefruit juice during the 7-day period preceding study initiation? Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken? Has s/he used any prescription drug during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation? Is s/he unable to refrain from the use of all concomitant medications during the study? Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Liver Transplantation normal fasting plasma glucose normal hemoglobin informed consent  type 1 diabetes mellitus or type 2 diabetes mellitus body mass index > 30 inflammatory bowel disease intestinal surgery serum creatinine > 250 µM and/or albuminuria ALAT > 2 x normal value Severe cardiac insufficiency in treatment with medicine which cannot be paused for 12 hours
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Vagotomy, Truncal normal fasting plasma glucose normal hemoglobin informed consent  type 1 diabetes mellitus or type 2 diabetes mellitus body mass index > 30 inflammatory bowel disease intestinal surgery serum creatinine > 250 µM and/or albuminuria ALAT > 2 x normal value Severe cardiac insufficiency in treatment with medicine which cannot be paused for 12 hours
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metabolic Syndrome Age >18 Informed consent Fasting blood glucose >95mg/dL Metabolic syndrome defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel-III (ATP-III) (3 out of 5) Abdominal obesity (waist circumference >102 in men or >88 in women) Elevated blood pressure (>135/>85) or drug treatment for elevated blood pressure Fasting blood glucose >100mg/dL or previously known type 2 diabetes mellitus High Density Lipoprotein (HDL) cholesterol <40 mg/dL (men) or <50 mg/dL (women) or drug treatment for low HDL cholesterol Triglycerides >150 mg/dL or drug treatment for elevated for high triglycerides HbA1C ≤7.0%  Drug treatment for diabetes mellitus Liver cirrhosis (biopsy proven) or elevated transaminases (>2x Upper Limit of Normla (ULN)) Inflammatory bowel disease (Crohns disease, ulcerative colitis) Celiac disease Alcohol abuse (more than 40g alcohol per day in the history) Clinical evidence of active infection Antibiotic treatment within 7 days prior to enrolment Use of immunomodulating agents within previous month (steroids etc.) Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the study Any severe illness unrelated to metabolic syndrome